Collaboration And License Agreement Sample Contracts

Applied Genetic Technologies Corp – COLLABORATION AND LICENSE AGREEMENT by and Between BIOGEN MA INC. And APPLIED GENETIC TECHNOLOGIES CORPORATION July 1, 2015 (September 11th, 2018)

This Collaboration and License Agreement (the "Agreement") is entered into as of July 1, 2015 (the "Execution Date"), by and between Biogen MA Inc., a corporation organized and existing under the laws of the Commonwealth of Massachusetts and having a principal place of business at 250 Binney Street, Cambridge, MA 02142 ("Biogen") and Applied Genetic Technologies Corporation, a corporation organized and existing under the laws of Delaware and having a principal place of business at 11801 Research Drive, Suite D, Alachua, FL 32615 ("AGTC"). Biogen and AGTC may each be referred to herein individually as a "Party" and collectively as the "Parties."

Mirati Therapeutics Inc. – Collaboration and License Agreement (August 20th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is entered into as of January 7, 2018 (the "Effective Date") by and among Mirati Therapeutics, Inc., a Delaware corporation, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA ("Mirati"), MethylGene Inc., a corporation organized under the laws of Canada and the wholly-owned subsidiary of Mirati, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA ("MethylGene"), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 ("BeiGene"). Mirati and BeiGene may be referred to herein individually as a "Party" and collectively as the "Parties." Mirati and MethylGene may be referred to herein individually as a "Licensor" and collectively as the "Licensors."

ChemoCentryx – Ladies and Gentlemen: As You Know, Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) and ChemoCentryx, Inc. (ChemoCentryx) Are Parties to That Certain Collaboration and License Agreement, Dated May 9, 2016, Amended May 22, 2017 (The VFMCRP Agreement), Pursuant to Which ChemoCentryx Granted VFMCRP an Exclusive License to Commercialize ChemoCentryxs Proprietary C5aR Inhibitor Known as CCX168 in Certain Countries. ChemoCentryx and Vifor (International) Ltd. (Vifor) Have Entered Into a Letter Agreement on 10 February 2017 to Expand the Territory and to Grant an Option to Vifor to Include Chi (August 9th, 2018)
ChemoCentryx – Amendment to Collaboration and License Agreement (August 9th, 2018)
ChemoCentryx – Ladies and Gentlemen: As You Know, Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) and ChemoCentryx, Inc. (ChemoCentryx) Are Parties to That Certain Collaboration and License Agreement, Dated December 22, 2016 (The VFMCRP Agreement), Pursuant to Which ChemoCentryx Granted VFMCRP an Exclusive License to Commercialize ChemoCentryxs Proprietary C5aR Inhibitor Known as CCX140 in Certain Countries. Capitalized Terms Used but Not Otherwise Defined in This Letter Agreement (This Letter) Will Have the Meanings Provided in the VFMCRP Agreement. The VFMCRP Agreement Was Originally Entered Into B (August 9th, 2018)
Proteostasis Therapeutics, Inc. – Amendment No. 6 to Collaboration and License Agreement (August 8th, 2018)

This Amendment No. 6 to Collaboration and License Agreement (this "Amendment No. 6") is made and effective as of April 23, 2018 by and between Proteostasis Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 200 Technology Square, 4th Floor, Cambridge, MA 02139 ("PTI") and Astellas Pharma Inc., a Japanese corporation having its principal place of business at 5-1 Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411, Japan ("Astellas"). Each of Astellas and PTI is sometimes referred to individually herein as a "Party" and collectively as the "Parties".

Editas Medicine, Inc. – Amended and Restated Collaboration and License Agreement (August 7th, 2018)

This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this "Agreement"), effective as of May 3, 2018 (the "Amendment Date"), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 ("Editas"), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 ("Juno") and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the "Original Agreement") dated as of May 26, 2015 (the "Original Agreement Effective Date").

Ultragenyx Pharmaceutical Inc. – Amendment No. 5 to Collaboration and License Agreement (August 3rd, 2018)

This Amendment No. 5 to the Collaboration and License Agreement ("Amendment") is made and entered into by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA ("UGNX").

- Initiated Phase 3 VOYAGER Clinical Trial of Avapritinib in Advanced Gastrointestinal Stromal Tumors - - Entered Into Exclusive Collaboration and License Agreement With CStone Pharmaceuticals to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China - (August 1st, 2018)

CAMBRIDGE, Mass., August 1, 2018 - Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2018.

First Amendment to Collaboration and License Agreement (August 1st, 2018)

This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the "Amendment") is entered into as of March 22, 2018 (the "Amendment Effective Date") by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA ("Exelixis") and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN ("Collaborator"). Exelixis and Collaborator may be referred to herein individually as a "Party" or collectively as the "Parties".

Orgenesis Inc – Collaboration and License Agreement _______ (July 17th, 2018)

This Collaboration and License Agreement (this "Agreement") is entered into as of 8th of JUNE , 2018 ("Effective Date"), by and between Mircod Limited., a company duly registered under the laws of Cyprus having an address at Nikodimou Milona 28, Limassol 3095 ("Mircod") and Orgenesis, Inc, having an address at 20271 Goldenrod Lane, Germantown, Md, 20876, USA ("ORGS").

Translate Bio, Inc. – Collaboration and License Agreement (June 12th, 2018)

This Collaboration and License Agreement is executed on June 8, 2018 (the Execution Date) by and between Translate Bio MA, Inc., with offices at 29 Hartwell Ave, Lexington, MA 02421, USA., a corporation registered under the laws of the State of Delaware (Translate Bio or TB) and Sanofi Pasteur Inc., a company incorporated under the laws of the state of Delaware, with offices at Discovery Drive, Swiftwater, PA 18370 USA (Sanofi). Sanofi and Translate Bio are sometimes referred to herein individually as a Party and collectively as the Parties.

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China (June 4th, 2018)

CAMBRIDGE, Mass. and SUZHOU, China, June 4, 2018 - Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, and CStone Pharmaceuticals, a privately-held biopharmaceutical company devoted to developing a new generation of innovative drugs, today announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies. Discovered and developed by Blueprint Medicines, avapritinib, BLU-554 and BLU-667 are potent and highly selective investigational kinase medicines that have each demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer. Blueprint Medicines will retain all rights to the licensed products in the rest of the world.

Puma Biotechnology – Collaboration and License Agreement (May 10th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this "Agreement"), entered into as of January 30th, 2018 (the "Effective Date"), is entered into by and between CANbridgepharma Limited, a corporation organized and existing under the laws of Hong Kong ("CANbridge"), and Puma Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware ("PUMA").

Collaboration and License Agreement (May 10th, 2018)

This Collaboration and License Agreement (this "Agreement") is made as of February 20, 2018 (the "Execution Date"), by and between Sangamo Therapeutics, Inc., a Delaware corporation having an office at 501 Canal Blvd., Richmond, CA 94804 ("Sangamo"), and Kite Pharma, Inc., a Delaware corporation having an office at 2225 Colorado Avenue, Santa Monica, CA 90404 ("Kite"). Gilead Sciences, Inc., a Delaware corporation having an office at 333 Lakeside Drive, Foster City, CA 94404 ("Gilead"), is a party to this Agreement solely for purposes of Section 16.18. Kite and Sangamo are referred to in this Agreement individually as a "Party" and collectively as the "Parties".

Wave Life Sciences Ltd. – Collaboration and License Agreement by and Among Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and Takeda Pharmaceutical Company Limited February 19, 2018 (May 9th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this "Agreement"), entered into as of February 19, 2018 (the "Execution Date"), is entered into by and among Wave Life Sciences USA, Inc., a corporation organized and existing under the Laws of the State of Delaware ("Wave US"), Wave Life Sciences UK Limited, a private limited company incorporated under the laws of England and Wales ("Wave UK", and together with Wave US, "Wave"), and Takeda Pharmaceutical Company Limited, a corporation organized and existing under the Laws of the Japan ("Takeda"). Wave and Takeda are referred to in this Agreement individually as a "Party" and collectively as the "Parties."

Revance Therapeutics – Collaboration and License Agreement (May 9th, 2018)

This Collaboration and License Agreement (this "Agreement") is made as of February 28, 2018 (the "Signing Date"), by and between Mylan Ireland Ltd., an Irish company having principal offices at South Bank House, Barrow Street, 6th Floor, Dublin, Ireland (together with its successors and assigns, "Mylan"), and Revance Therapeutics, Inc., a Delaware corporation, having principal offices at 7555 Gateway Blvd., Newark, CA 94560 (together with its successors and assigns, "Revance"). Mylan and Revance may be referred to herein by name or individually, as a "Party" and collectively, as the "Parties."

Mirati Therapeutics Inc. – Collaboration and License Agreement (May 7th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is entered into as of January 7, 2018 (the "Effective Date") by and among Mirati Therapeutics, Inc., a Delaware corporation, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA ("Mirati"), MethylGene Inc., a corporation organized under the laws of Canada and the wholly-owned subsidiary of Mirati, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA ("MethylGene"), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 ("BeiGene"). Mirati and BeiGene may be referred to herein individually as a "Party" and collectively as the "Parties." Mirati and MethylGene may be referred to herein individually as a "Licensor" and collectively as the "Licensors."

Amendment No. 1 to Global Collaboration and License Agreement (May 1st, 2018)

This Amendment No. 1 to Global Collaboration and License Agreement (this "Amendment") is dated as of March 15, 2018, by and between INCYTE CORPORATION, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter "Incyte"), and MACROGENICS, INC., a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 ("MacroGenics", together with Incyte, the "Parties" and each separately, a "Party"), and is meant to amend that certain Global Collaboration and License Agreement, dated as of October 24, 2017, between Incyte and MacroGenics (the "Agreement"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

Morphosys Ag – Collaboration and License Agreement (April 11th, 2018)
Homology Medicines, Inc. – Collaboration and License Agreement by and Between Homology Medicines, Inc. And Novartis Institutes for Biomedical Research, Inc. Dated November 6, 2017 (March 23rd, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this Agreement) is entered into this 6th day of November, 2017 (the Effective Date), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (HMI), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (NVS). HMI and NVS are sometimes referred to herein individually as a Party and collectively as the Parties.

Morphosys Ag – Collaboration and License Agreement (March 22nd, 2018)
Homology Medicines, Inc. – Collaboration and License Agreement by and Between Homology Medicines, Inc. And Novartis Institutes for Biomedical Research, Inc. Dated November 6, 2017 (March 19th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this Agreement) is entered into this 6th day of November, 2017 (the Effective Date), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (HMI), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (NVS). HMI and NVS are sometimes referred to herein individually as a Party and collectively as the Parties.

Aralez Pharmaceuticals Inc. – Amendment No. 2 to Amended and Restated Collaboration and License Agreement for the United States (March 14th, 2018)

This AMENDMENT NO. 2 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the "Amendment") is made by and between POZEN Inc., a Delaware corporation ("POZEN"), and Horizon Pharma USA, Inc., a Delaware corporation ("Horizon" or "Licensee," and together with POZEN, the "Parties"). Reference is made to that certain Amended and Restated Collaboration and License Agreement for the United States, dated as of November 18, 2013, by and between POZEN and Horizon, as successor in interest to AstraZeneca AB ("AZ"), as amended (the "Agreement"). All capitalized terms not herein defined shall have the meaning ascribed to them in the Agreement. This Amendment shall be effective as of February 22, 2018.

Homology Medicines, Inc. – Collaboration and License Agreement by and Between Homology Medicines, Inc. And Novartis Institutes for Biomedical Research, Inc. Dated November 6, 2017 (March 2nd, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this Agreement) is entered into this 6th day of November, 2017 (the Effective Date), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (HMI), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (NVS). HMI and NVS are sometimes referred to herein individually as a Party and collectively as the Parties.

Global Collaboration and License Agreement by and Between Macrogenics, Inc. And Incyte Corporation (February 27th, 2018)

This GLOBAL COLLABORATION AND LICENSE AGREEMENT ("Agreement") is entered into as of October 24, 2017 (the "Execution Date"), by and between INCYTE CORPORATION, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter "Incyte"), and MACROGENICS, INC., a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 ("MacroGenics"). Incyte and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Third Amendment to Collaboration and License Agreement (February 26th, 2018)

This THIRD AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the "Third Amendment") is entered into as of October 26, 2017 (the "Third Amendment Effective Date") by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA ("Exelixis") and Ipsen Pharma SAS, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France ("Licensee"). Exelixis and Licensee may be referred to herein individually as a "Party" or collectively as the "Parties".

Ultragenyx Pharmaceutical Inc. – Amendment No. 4 to Collaboration and License Agreement (February 21st, 2018)

This Amendment No. 4 to the Collaboration and License Agreement (this "Amendment") is made and entered into as of January 29, 2018 ("Effective Date"), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100- 0004, Japan ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni, Novato, California 94949, USA ("UGNX'').

Ultragenyx Pharmaceutical Inc. – Amendment No. 3 to Collaboration and License Agreement (February 21st, 2018)

This Amendment No. 3 to the Collaboration and License Agreement ("Amendment") is made and entered into by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA ("UGNX").

Ultragenyx Pharmaceutical Inc. – Amendment No. 2 to Collaboration and License Agreement (February 21st, 2018)

This Amendment No. 2 to the Collaboration and License Agreement ("Amendment") is made and entered into by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA ("UGNX").

Ultragenyx Pharmaceutical Inc. – 3rd AMENDMENT TO RESEARCH, COLLABORATION AND LICENSE AGREEMENT (February 21st, 2018)

This THIRD AMENDMENT ("Third Amendment") is entered into as of October 30, 2017 (the "Third Amendment Effective Date") by and between Dimension Therapeutics Inc., having its principal offices at 840 Memorial Drive, Cambridge, MA 02139 ("Licensee"), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 ("Penn"). Licensee and Penn are sometimes hereinafter referred to collectively as the "Parties" and individually as a "Party."

Ultragenyx Pharmaceutical Inc. – Collaboration and License Agreement (February 21st, 2018)

This COLLABORATION AND LICENSE AGREEMENT ("Agreement") is entered into as of June 18, 2014 ("Effective Date") by and between Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13th Floor, Cambridge, MA 02142 ("Dimension"), and Bayer HealthCare LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 455 Mission Bay Blvd South, San Francisco, CA 94158 ("Bayer"). Dimension and Bayer are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Global Collaboration and License Agreement by and Between Macrogenics, Inc. And Incyte Corporation (February 15th, 2018)

This GLOBAL COLLABORATION AND LICENSE AGREEMENT ("Agreement") is entered into as of October 24, 2017 (the "Execution Date"), by and between INCYTE CORPORATION, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter "Incyte"), and MACROGENICS, INC., a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 ("MacroGenics"). Incyte and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Homology Medicines, Inc. – Collaboration and License Agreement by and Between Homology Medicines, Inc. And Novartis Institutes for Biomedical Research, Inc. Dated November 6, 2017 (January 30th, 2018)

THIS COLLABORATION AND LICENSE AGREEMENT (this Agreement) is entered into this 6th day of November, 2017 (the Effective Date), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (HMI), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (NVS). HMI and NVS are sometimes referred to herein individually as a Party and collectively as the Parties.

Neurokine Pharmaceuticals Inc. – Pivot - Solmic Collaboration and License Agreement (December 15th, 2017)

This COLLABORATION AND LICENSE AGREEMENT is made this 23rd day of September 2017 (hereinafter the "Effective Date"), by and between PIVOT PHARMACEUTICALS INC., a corporation organized under the laws of British Columbia with an address c/o 1275 West 6th Street, Suite 300, Vancouver, BC V6C 1A6 (hereinafter "PIVOT") and SolMic GmbH, a corporation organized under the laws of Germany with an address Merowingerplatz 1a, 40225 Dusseldorf, Germany, (hereinafter "SOLMIC"). PIVOT and SOLMIC herein may be referred to individually as "Party" or together as "Parties."